1. Introduction {#s1}
===============

It has been suggested that performing a comprehensive geriatric assessment (CGA) which includes variables related to frailty, mental and physical status, social support, and overall health prior to transcatheter aortic valve implantation (TAVI) may provide valuable information to aid candidate selection among elderly patients.[@b1],[@b2] Recent evidence from a single-centre observational study suggests that the Multidimensional Prognostic Index (MPI), which was originally developed to assess mortality after hospitalisation of elderly patients,[@b3] can accurately predict outcomes for up to twelve months post-procedure in geriatric patients undergoing TAVI.[@b4] Similarly, in a previous analysis of the present registry (CGA-TAVI), we found a higher MPI to be predictive of death/stroke by three months post-TAVI.[@b5] In that previous analysis, we also assessed the Silver Code (SC) and Short Physical Performance Battery (SPPB) tools,[@b6],[@b7] and found the latter to also have some predictive value for short-term outcomes in elderly patients post-TAVI.[@b5]

In the present manuscript, we analysed the CGA-TAVI registry data with the aim of assessing the value of the two principal CGA tools (MPI and SPPB) from the previous analysis for predicting outcomes in the year following TAVI.

2. Methods {#s2}
==========

The design and rationale of the prospective, international, multicentre, observational CGA-TAVI registry has been previously described.[@b8] Consequently, only a brief overview is included herein. Elderly patients with severe aortic stenosis (AS) were enrolled at one of three hospitals or medical centres in Italy, the Netherlands and Canada between August 2013 and December 2015. The study was approved by the responsible ethics committee at each participating site. All subjects gave their written informed consent to participate.

2.1. Inclusion/exclusion criteria {#s2a}
---------------------------------

Patients meeting the following criteria were eligible for inclusion: severe, symptomatic, and calcific AS; age ≥ 80 years; scheduled to undergo transapical- or transfemoral-TAVI; adequate time to perform CGA prior to the procedure (*i.e.*, not an emergency); and ability to participate in follow-up examinations.

2.2. Baseline assessment {#s2b}
------------------------

At baseline, details of patient demographics, comorbidities, prior cardiovascular interventions, cardiac characteristics, and surgical risk were documented. A geriatrician also carried out the CGA, with each patient evaluated using three assessment tools: the MPI (a mean of eight different components);[@b5],[@b8] the SPPB (consisting of repeated chair stands, balance testing, and walking 2.44 meters);[@b7] and the SC (an algorithm based on administrative data).[@b6] For the MPI and SC, a lower score indicates a better prognosis; while the inverse is true for the SPPB. Data for the SC are not included in the current analysis, because it did not show any predictive ability in the prior analysis of short-term outcomes in the study population.[@b5]

2.3. Follow-up {#s2c}
--------------

Patients were followed-up at thirty days and three months (data previously published),[@b5] and again at one year by either telephone or outpatient clinic visit. Recorded outcomes at one year were death, non-fatal stroke, hospitalisation for valve-related symptoms or worsening congestive heart failure, major vascular complications, repeat procedure for valve dysfunction, valve thrombosis, and thrombo-embolic events (all as defined by the Valve Academic Research Consortium-2 criteria),[@b9] and selected combinations thereof. These data were used to identify any associations between baseline MPI and SPPB scores (or postoperative change in scores) and clinical outcomes at one year. The main endpoints of interest for the current analysis were all-cause mortality and a composite endpoint of death and/or non-fatal stroke.

2.4. Statistical analysis {#s2d}
-------------------------

Data are presented using descriptive statistics, with absolute values and percentages given for categorical variables and means ± SD for continuous variables. For the purposes of assessing survival, Kaplan-Meier analysis was carried out, with patients stratified into good and poor prognosis groups based on their scores in each of the GCA tools (MPI: mean of 0.0--0.33 and 0.34--1.0, respectively; and SPPB: 7--12 and 0--6 points, respectively). The value of each CGA tool and each of their components for predicting primary and secondary outcomes at one year was assessed using logistic regression. Regression results are presented as odds ratio (OR) with 95% confidence intervals (CI) and *P*-values. Data were analysed using IBM SPSS statistics version 24 (IBM corporation, Amonk, New York, USA). In all cases, significance was determined by a *P*-value \< 0.05.

3. Results {#s3}
==========

3.1. Baseline patient characteristics {#s3a}
-------------------------------------

The baseline characteristics of the 71 patients included in the analysis have been described before.[@b5] In short, the mean ± SD age of the study population was 85.4 ± 2.9 years, patients had a body mass index of 24.7 ± 3.7 kg/m^2^, the most common comorbidities were hypertension (83.1%) and coronary artery disease (53.5%), and more than 80% of patients were in New York Heart Association (NYHA) class III or IV. AS-related symptoms included class III angina (10%), dizziness on exertion (7.0%) and syncope (7.0%); the mean aortic valve gradient was 50.5 ±14.1 mmHg and mean left ventricular ejection fraction was 50.9% ± 12.0%. In terms of surgical risk, mean ± SD values for the log EuroSCORE I and Society of Thoracic Surgeons score were 22.5 ± 13.2 and 5.8 ± 3.9, respectively.

3.2. Outcomes at one year {#s3b}
-------------------------

Outcomes at one year (mortality, non-fatal complications and combined endpoints) are summarised in [Table 1](#jgc-16-06-468-t01){ref-type="table"} and were available for 70 patients (98.6%). By one year after TAVI, 10 of 70 (14.1%) patients had died, while 12 of 69 (17.4%) had met the combined endpoint of death and/or non-fatal stroke, and 26 of 69 (37.7%) had met the combined endpoint of death and/or re-hospitalisation and/or non-fatal stroke.

###### Outcomes within one year after TAVI by MPI/SPPB score, and association between MPI/SPPB score and outcomes (logistic regression analysis).

  MPI score                                                                     Total       High risk (0.34 to 1.00)   Low risk (0 to 0.33)        Univariable         Multivariable\*                           
  ------------------------------------------------------------------------ --------------- -------------------------- ----------------------- --------------------- --------------------- ---------------------- -------
  All-cause mortality                                                       10/70 (14.1%)         7/28 (25.0%)              3/42 (7.1%)        4.33 (1.01--18.53)           0.048          36.13 (2.77--470.78)   0.006
  Combined endpoint                                                                                                                                                                                              
  Death and/or re-hospitalisation                                           25/69 (36.2%)        13/28 (46.4%)             12/41 (29.3%)        2.09 (0.77--5.71)           0.15            3.66 (1.01--13.33)    0.049
  Death and/or non-fatal stroke                                             12/69 (17.4%)         7/28 (25.0%)             5/41 (12.2%)         2.40 (0.68--8.53)           0.18           10.10 (1.48--68.75)    0.018
  Death, re-hospitalisation and/or stroke                                   26/69 (37.7%)        13/28 (46.4%)             13/41 (31.7%)        1.87 (0.69--5.03)           0.22            2.65 (0.79--8.92)     0.11
  Death, re-hospitalisation, stroke, AKI, MVC, repeat procedure, MI, PPI    33/69 (47.8%)        15/28 (53.6%)             18/41 (43.9%)        1.47 (0.56--3.87)           0.43            1.49 (0.50--4.49)     0.47
  Non-fatal complications                                                                                                                                                                                        
  Non-valve related re-hospitalization                                      14/69 (20.3%)         6/28 (21.4%)             8/41 (19.5%)         1.13 (0.34--3.69)           0.85            1.48 (0.36--6.15)     0.59
  Valve-related re-hospitalisation                                           6/69 (8.7%)          3/28 (10.7%)              3/41 (7.3%)         1.52 (0.28--8.14)           0.63            0.78 (0.09--6.78)     0.82
  Non-fatal stroke                                                           2/69 (2.9%)           0/28 (0%)                2/41 (4.9%)                \-                    \-                     \-             \-
  Acute kidney injury (stage 2 or 3)                                         4/69 (5.8%)          3/28 (10.7%)              1/41 (2.4%)        4.80 (0.47--48.73)           0.19           13.00 (0.31--540.14)   0.18
  Major vascular complication                                                2/69 (2.9%)          2/28 (7.1%)                0/41 (0%)                 \-                    \-                     \-             \-
  Repeat procedure for valve dysfunction                                     1/69 (1.4%)          1/28 (3.6%)                0/41 (0%)                 \-                    \-                     \-             \-
  Myocardial infarction                                                      2/69 (2.9%)           0/28 (0%)                2/41 (4.9%)                \-                    \-                     \-             \-
  PPI                                                                       11/69 (15.9%)         4/28 (14.3%)             7/41 (17.1%)         0.81 (0.21--3.08)           0.76            0.44 (0.09--2.10)     0.30
                                                                                                                                                                                                                 
  **SPPB-score**                                                              **Total**      **High risk (0 to 6)**    **Low risk (7 to12)**     **Univariable**     **Multivariable\***                         
  **OR (95% CI)**                                                           ***P*-value**       **OR (95% CI)**            ***P*-value**                                                                         
                                                                                                                                                                                                                 
  All-cause mortality                                                       10/70 (14.1%)         9/39 (23.1%)              1/31 (3.2%)        9.00 (1.07--75.51)           0.043           7.09 (0.70--71.89)    0.097
  Combined endpoint                                                                                                                                                                                              
  Death and/or re-hospitalisation                                           25/69 (36.2%)        16/38 (42.1%)             9/31 (29.0%)         1.78 (0.65--4.87)           0.26            1.37 (0.41--4.53)     0.61
  Death and/or non-fatal stroke                                             12/69 (17.4%)        10/38 (26.3%)              2/31 (6.5%)        5.18 (1.04--25.77)           0.045           8.79 (0.93--83.34)    0.058
  Death, re-hospitalisation and/or stroke                                   26/69 (37.7%)        17/38 (44.7%)             9/31 (29.0%)         1.98 (0.72--5.41)           0.18            1.62 (0.50--5.19)     0.42
  Death, re-hospitalisation, stroke, AKI, MVC, repeat procedure, MI, PPI    33/69 (47.8%)        23/38 (60.5%)             10/31 (32.3%)        3.22 (1.19--8.71)           0.021           3.19 (1.03--9.89)     0.045
  Non-fatal complications                                                                                                                                                                                        
  Non-valve related re-hospitalization                                      14/69 (20.3%)         8/38 (21.1%)             6/31 (19.4%)         1.11 (0.34--3.63)           0.86            0.94 (0.21--4.09)     0.93
  Valve-related re-hospitalisation                                           6/69 (8.7%)          3/38 (7.9%)               3/31 (9.7%)         0.80 (0.15--4.27)           0.79            0.53 (0.08--3.55)     0.52
  Non-fatal stroke                                                           2/69 (2.9%)          1/38 (2.6%)               1/31 (3.2%)        0.81 (0.049--13.51)          0.88                    \-             \-
  Acute kidney injury (stage 2 or 3)                                         4/69 (5.8%)          3/38 (7.9%)               1/31 (3.2%)        2.57 (0.25--26.04)           0.42            1.09 (0.07--17.86)    0.95
  Major vascular complication                                                2/69 (2.9%)          2/38 (5.3%)                0/31 (0%)                 \-                    \-                     \-             \-
  Repeat procedure for valve dysfunction                                     1/69 (1.4%)           0/38 (0%)                1/31 (3.2%)                \-                    \-                     \-             \-
  Myocardial infarction                                                      2/69 (2.9%)           0/38 (0%)                2/31 (6.5%)                \-                    \-                     \-             \-
  PPI                                                                       11/69 (15.9%)         9/38 (23.7%)              2/31 (6.5%)        4.50 (0.89--22.66)           0.07            4.07 (0.72--22.94)    0.11

Data are presented as *n* /N (%) unless other indicated. \*Adjusted for age, gender, NYHA class and surgical risk (EuroScore). *n* /N refers the ratio of number of patients with outcome to number of patients at risk. AKI: acute kidney injury; MI: myocardial infarction; MPI: multidimensional prognostic index; MVC: major vascular complication; OR: odds ratio; PPI: permanent pacemaker implantation; SPPB: short physical performance battery; TAVI: transcatheter aortic valve implantation.

3.3. Association of MPI and SPPB with one-year outcomes {#s3c}
-------------------------------------------------------

Outcomes within one year after TAVI for patients stratified into high- and low-risk groups according to MPI score are summarised in [Table 1](#jgc-16-06-468-t01){ref-type="table"}, together with the results of logistic regression analysis evaluating the relationship between baseline MPI score and outcomes. After adjustment for other baseline characteristics (including age, gender, NYHA class, and EuroScore surgical risk score), a high-risk MPI score was associated with an increased risk of all-cause mortality (adjusted OR = 36.13, 95% CI: 2.77--470.78, *P* = 0.006) and the combined endpoint of death and/or non-fatal stroke (aOR = 10.10, 95% CI: 1.48--68.75, *P* = 0.018). Kaplan-Meier analysis curves stratified by MPI risk group are shown for survival ([Figure 1A](#jgc-16-06-468-g001){ref-type="fig"}), freedom from death and/or non-fatal stroke ([Figure 1C](#jgc-16-06-468-g001){ref-type="fig"}) and freedom from death/hospitalisation/stroke ([Figure 1E](#jgc-16-06-468-g001){ref-type="fig"}).

![Kaplan-Meier survival analysis stratified by MPI group (A), SPPB group (B) and score & Kaplan-Meier analysis for the freedom from death and stroke stratified by MPI group (C), SPPB group (D) and score & Kaplan-Meier analysis for the freedom from death, re-hospitalization and stroke stratified by MPI group (E), SPPB group (F) and score.\
MPI: multidimensional prognostic index; SPPB: short physical performance battery.](jgc-16-06-468-g001){#jgc-16-06-468-g001}

Outcomes within one year after TAVI for patients stratified by SPPB risk, and the results of the analysis of the relationship between baseline SPPB score and outcomes, are summarised in [Table 1](#jgc-16-06-468-t01){ref-type="table"}. After adjustment for other baseline characteristics, no significant associations were found between a high-risk SPPB score and mortality, or the combined endpoints of death and/or non-fatal stroke, or death/hospitalisation/stroke. However, a high-risk SPPB score was independently associated with an increased risk of a composite endpoint comprising all fatal and non-fatal endpoints evaluated (*i.e.*, death/hospitalisation/non-fatal stroke/acute kidney injury/major vascular complication/repeated procedure/myocardial infarction/permanent pacemaker implantation, aOR = 3.19, 95% CI: 1.03--9.89, *P* = 0.045). Kaplan-Meier analysis curves stratified by SPPB risk group are shown for survival ([Figure 1B](#jgc-16-06-468-g001){ref-type="fig"}), freedom from death and/or non-fatal stroke ([Figure 1D](#jgc-16-06-468-g001){ref-type="fig"}) and freedom from death/re-hospitalization/stroke ([Figure 1F](#jgc-16-06-468-g001){ref-type="fig"}).

3.4. Association of MPI and SPPB components with one-year outcomes {#s3d}
------------------------------------------------------------------

Associations between components of the MPI and SPPB and key combined outcomes at one year are summarised in [Table 2](#jgc-16-06-468-t02){ref-type="table"} (association with death and/or re-hospitalization and/or stroke and association with death and/or stroke). After adjusting for baseline characteristics, the only MPI components associated with the combined endpoint of death and/or stroke at one year were worse Activities of Daily Living (ADL) score (aOR = 13.21, 95% CI: 1.54--113.72, *P* = 0.019) and worse Exton-Smith Scale (ESS) score (aOR = 9.30, 95% CI: 1.63--53.19, *P* = 0.012). The only MPI components associated with an increased risk of the combined endpoint of death and/or re-hospitalization and/or stroke at one year were worse Mini Nutritional Assessment (MNA) score (aOR = 3.42, 95% CI: 1.04--11.18, *P* = 0.042) and worse ESS score (aOR = 13.72, 95% CI: 1.64--115.06, *P* = 0.016). No SPPB components were significantly associated with either of these outcomes in the adjusted analysis.

###### Association of MPI and SPPB components with combined outcome of mortality and/or re-hospitalization and/or stroke and association of MPI and SPPB components with combined outcome of mortality and/or stroke at one year after TAVI.

                                                                Mortality, any re-hospitalization, or stroke       Univariable Events in high *vs*. low risk       Multivariable^\*^ Events in high *vs*. low risk                                             
  ---------------------------------------------------------- -------------------------------------------------- ----------------------------------------------- ----------------------------------------------------- ----------------- ---------------------- ---------------
  MPI                                                                          13/28 (46.4%)                                     13/41 (31.7%)                                    1.87 (0.69--5.03)                         0.22          2.65 (0.79--8.92)         0.11
  Co-habitation status                                                         11/29 (37.9%)                                     15/40 (37.5%)                                    1.02 (0.38--2.73)                         0.97          1.45 (0.43--4.90)         0.55
  Current medication use                                                       25/68 (36.8%)                                      1/1 (100%)                                             \-                                  \-                   \-                 \-
  ADL score                                                                     5/7 (71.4%)                                      21/62 (33.9%)                                   4.88 (0.87--27.32)                         0.071         4.26 (0.67--27.18)        0.13
  IADL score                                                                    8/17 (47.1%)                                     18/52 (34.6%)                                    1.68 (0.55--5.10)                         0.36          1.377 (0.38--5.03)        0.63
  SPMSQ score                                                                    1/1 (100%)                                      25/68 (36.8%)                                           \-                                  \-                   \-                 \-
  CIRS CI                                                                      25/67 (37.3%)                                      1/2 (50.0%)                                     0.60 (0.04--9.94)                         0.72          0.65 (0.03--14.32)        0.65
  MNA score                                                                    16/35 (45.7%)                                     10/34 (29.4%)                                    2.02 (0.75--5.46)                         0.17          3.42 (1.04--11.18)        0.042
  ESS                                                                           7/9 (77.8%)                                      19/60 (31.7%)                                   7.55 (1.43--39.84)                         0.017        13.72 (1.64--115.06)       0.016
                                                                                                                                                                                                                                                               
                                                                 **(SPPB = 0 to 6 or components = 0 to 2)**       **(SPPB = 7 to 12 or components = 3 to 4)**                      **OR (95% CI)**                      ***P*-value**      **OR (95% CI)**      ***P*-value**
                                                                                                                                                                                                                                                               
  SPPB                                                                         17/38 (44.7%)                                     9/31 (29.0%)                                     1.98 (0.72--5.41)                         0.18          1.62 (0.50--5.19)         0.42
  Repeated Chair Stands                                                        21/58 (36.2%)                                     5/11 (45.5%)                                     0.68 (0.19--2.50)                         0.56          0.45 (0.09--2.16)         0.32
  Balance Testing                                                              15/31 (48.4%)                                     11/38 (28.9%)                                    2.30 (0.85--6.22)                         0.10          1.97 (0.67--5.81)         0.22
  Eight-foot walk                                                              21/45 (46.7%)                                     5/24 (20.8%)                                    3.33 (1.06--10.46)                         0.040         3.40 (0.93--12.46)        0.064
                                                                                                                                                                                                                                                               
                                                                          **Mortality and stroke**               **Univariable Events in high *vs*. low risk**   **Multivariable^\*^ Events in high *vs*. low risk**                                           
  **High risk (MPI = 0.34 to 1 or components = 0.5 to 1)**    **Low risk (MPI = 0 to 0.33 or components = 0)**                  **OR (95% CI)**                                     ***P*-value**                      **OR (95% CI)**      ***P*-value**      
                                                                                                                                                                                                                                                               
  MPI                                                                           7/28 (25.0%)                                     5/41 (12.2%)                                     2.40 (0.68--8.53)                         0.18         10.10 (1.48--68.75)        0.018
  Co-habitation status                                                          5/29 (17.2%)                                     7/40 (17.5%)                                     0.98 (0.28--3.47)                         0.98          1.88 (0.40--8.76)         0.42
  Current medication use                                                       12/68 (17.6%)                                       0/1 (0%)                                              \-                                  \-                   \-                 \-
  ADL score                                                                     3/7 (42.9%)                                      9/62 (14.5%)                                    4.42 (0.84--23.12)                         0.08         13.21 (1.54--113.72)       0.019
  IADL score                                                                    3/17 (17.6%)                                     9/52 (17.3%)                                     1.02 (0.24--4.32)                         0.97          1.10 (0.22--5.63)         0.91
  SPMSQ score                                                                     0/1 (0%)                                       12/68 (17.6%)                                           \-                                  \-                   \-                 \-
  CIRS CI                                                                      12/67 (17.9%)                                       0/2 (0%)                                              \-                                  \-                   \-                 \-
  MNA score                                                                     7/35 (20.0%)                                     5/34 (14.7%)                                     1.45 (0.41--5.11)                         0.56          2.40 (0.51--11.37)        0.27
  ESS                                                                           5/9 (55.6%)                                      7/60 (11.7%)                                    9.46 (2.04--43.84)                         0.004         9.30 (1.63--53.19)        0.012
                                                                                                                                                                                                                                                               
                                                                 **(SPPB = 0 to 6 or components = 0 to 2)**       **(SPPB = 7 to 12 or components = 3 to 4)**                      **OR (95% CI)**                      ***P*-value**      **OR (95% CI)**      ***P*-value**
                                                                                                                                                                                                                                                               
  SPPB                                                                         10/38 (26.3%)                                      2/31 (6.5%)                                    5.18 (1.04--25.77)                         0.045         8.79 (0.93--83.34)        0.058
  Repeated Chair Stands                                                        10/58 (17.2%)                                     2/11 (18.2%)                                     0.94 (0.18--5.01)                         0.94          0.91 (0.12--7.14)         0.93
  Balance Testing                                                               9/31 (29.0%)                                      3/38 (7.9%)                                    4.77 (1.16--19.57)                         0.03          4.44 (0.95--20.73)        0.058
  Eight-foot walk                                                              11/45 (24.4%)                                      1/24 (4.2%)                                    7.44 (0.90--61.65)                         0.06                  \-                 \-

Data are presented as *n* /N (%) unless other indicated. \*Adjusted for age, gender, NYHA class and surgical risk (EuroScore). *n* /N refers the ratio of number of patients with outcome to number of patients at risk. ADL: activities of daily living; CIRS: cumulative illness rating scale; ESS: exton-smith scale; IADL: instrumental activities of daily living; MNA: mini nutritional assessment; MPI: multidimensional prognostic index; OR: odds ratio; SPMSQ: short portable mental status questionnaire; SPPB: short physical performance battery.

3.5. Association of 3-month changes in MPI or SPPB with one-year outcomes {#s3e}
-------------------------------------------------------------------------

The relationship between a worsening MPI or SPPB score within three months after TAVI and outcomes at one year is summarised in [Table 3](#jgc-16-06-468-t03){ref-type="table"}. A worsening (increasing) MPI score at three months post-TAVI was associated with an increased risk of the combined endpoint of death and/or non-fatal stoke at one year in the adjusted analysis (aOR = 95.16, 95% CI: 3.41--2657.01). No significant independent relationships were found between worsening SSPB and one-year outcomes.

###### Outcomes at one year with respect to worsening of MPI or SPPB within three months after TAVI.

                                                                             Total       Score components available   Increasing MPI (*n* = 17)   Decreasing SPPB (*n* = 5)                                                               
  --------------------------------------------------------------------- --------------- ---------------------------- --------------------------- --------------------------- ----------------------- ------------- ---------------------- -----------------------
  All-cause mortality                                                    10/70 (14.1%)          4/56 (7.1%)                 4/17 (23.5%)                     \-                        \-              0/5 (0%)              \-                     \-
  Combined endpoint                                                                                                                                                                                                                       
  Death and/or hospitalisation                                           25/69 (36.2%)         17/55 (30.9%)                6/17 (35.3%)              1.34 (0.40--4.52)         1.10 (0.27--4.56)     1/5 (20.0%)    0.53 (0.06--5.14)       0.46 (0.04--5.66)
  Death and/or non-fatal stroke                                          12/69 (17.4%)          6/55 (10.9%)                5/17 (29.4%)            15.42 (1.64--145.34)      95.16 (3.41--2657.01)   1/5 (20.0%)    2.25 (0.21--24.27)     3.38 (0.25--44.91)
  Death, hospitalisation and/or stroke                                   26/69 (37.7%)         18/55 (32.7%)                7/17 (41.2%)              1.72 (0.52--5.67)         1.69 (0.41--6.95)     2/5 (40.0%)    1.42 (0.22--9.33)      1.72 (0.22--13.68)
  Death, hospitalisation, stroke, AKI, MVC, repeat procedure, MI, PPI    33/69 (47.8%)         23/55 (41.8%)                9/17 (52.9%)              1.93 (0.61--6.14)         2.02 (0.54--7.62)     2/5 (40.0%)    0.92 (0.14--6.01)       0.96 (0.13--7.07)
  Non-fatal complications                                                                                                                                                                                                                 
  Non-valve related re-hospitalization                                   14/69 (20.3%)         12/55 (21.8%)                4/17 (23.5%)              1.15 (0.30--4.52)         0.86 (0.16--4.54)      0/5 (0%)              \-                     \-
  Valve-related hospitalisation                                           6/69 (8.7%)           4/55 (7.3%)                  1/17 (5.9%)              0.73 (0.07--7.56)        1.32 (0.12--14.86)     1/5 (20.0%)    3.92 (0.33--46.90)     2.52 (0.20--32.32)
  Non-fatal stroke                                                        2/69 (2.9%)           2/55 (3.6%)                  1/17 (5.9%)             2.31 (0.14--39.31)       19.61 (0.47--812.40)    1/5 (20.0%)   12.25 (0.64--234.81)   51.99 (0.88--3060.37)
  Acute kidney injury (stage 2 or 3)                                      4/69 (5.8%)           2/55 (3.6%)                   0/17 (0%)                      \-                        \-             1/5 (20.0%)   12.25 (0.64--234.81)   10.57 (0.30--378.98)
  Major vascular complication                                             2/69 (2.9%)            0/55 (0%)                    0/17 (0%)                      \-                        \-              0/5 (0%)              \-                     \-
  Repeat procedure for valve dysfunction                                  1/69 (1.4%)           1/55 (1.8%)                   0/17 (0%)                      \-                        \-             1/5 (20.0%)            \-                     \-
  Myocardial infarction                                                   2/69 (2.9%)           1/55 (1.8%)                   0/17 (0%)                      \-                        \-              0/5 (0%)              \-                     \-
  PPI                                                                    11/69 (15.9%)          7/55 (12.7%)                2/17 (11.8%)              0.88 (0.15--5.06)         0.44 (0.05--3.70)      0/5 (0%)              \-                     \-

Data are presented as *n* /N (%) unless other indicated. \*Adjusted for age, gender, NYHA class and surgical risk (EuroScore). *n* /N refers the ratio of number of patients with outcome to number of patients at risk. AKI: acute kidney injury; MI: myocardial infarction; MPI: multidimensional prognostic index; MVC: major vascular complication; OR: odds ratio; PPI: permanent pacemaker implantation; SPPB: short physical performance battery; TAVI: transcatheter aortic valve implantation.

4. Discussion {#s4}
=============

This analysis of the CGA-TAVI registry data found that the MPI, but not the SPPB, showed value for predicting the likelihood of death and a combination of death and/or non-fatal stroke by one year after TAVI in elderly patients.

The rate of all-cause mortality at one year after TAVI (14.1%) in the CGA-TAVI registry was consistent with rates reported in large studies of elderly patients (mean age \> 80 years) with a similar level of surgical risk (12.5%--17.1%).[@b10]--[@b14] The incidence of non-fatal stroke at one year (2.9%) was also within the range reported for other studies (2.2%--4.3%).[@b10],[@b11],[@b13],[@b14] The current analysis reported rates of valve-related and non-valve--related re-hospitalisation of 8.7% and 20.3%, respectively. Although not directly comparable because of the different definitions used, other studies have reported rates of 3.2%--8.1% for rehospitalisation related to the valve or heart failure[@b13],[@b14] and 17.1% for any rehospitalisation.[@b11]

The incorporation of CGA measures into the clinical assessment of AS candidates for TAVI may improve the assessment of procedural risk and/or risk of adverse outcome at follow-up in this generally elderly population.[@b8],[@b15] Studies have shown the potential of various multi-component tools for predicting morbidity and mortality outcomes after elective cardiac surgical procedures[@b16] and specifically after TAVI.[@b15], [@b17]--[@b21]

The MPI is derived from a standard CGA that includes clinical, functional, cognitive, nutritional, and social parameters.[@b3] Studies have shown that higher MPI scores are associated with higher rates of mortality and other adverse outcomes in older hospitalised patients,[@b3],[@b22],[@b23] including those with heart failure[@b24] or transient ischemic attack[@b25]. Limited information on its role specifically in TAVI patients is available. A prospective, single-centre, observational study involving 116 patients (mean age 86 years, mean EuroSCORE 19.2%) found that the MPI was able to predict the risk of mortality at six and twelve months after TAVI.[@b4] In addition, a previous analysis of data from our CGA-TAVI registry found that the MPI had value for predicting the likelihood of a composite of death and/or hospitalisation and a composite of death and/or non-fatal stroke within the first three months after TAVI.[@b5] The current analysis assessed the value of the MPI for predicting outcomes up to one year after TAVI and found that, after adjusting for baseline characteristics, MPI score was predictive for all-cause mortality and the combination of death and/or non-fatal stroke at this timepoint, but not for the composite of death and/or hospitalisation. Thus, based on CGA-TAVI registry data, the MPI was predictive of death and/or non-fatal stroke at both three months and one year after TAVI. However, its predictive value for death and/or hospitalisation in the short term was not maintained through to one year. The previous analysis did not evaluate the relationship specifically with all-cause mortality at three months.

The SPPB involves physical performance tests that assess lower extremity function.[@b7] Lower scores on the SPPB have been shown to be predictive of an increased risk of death and/or rehospitalisation in older adults with acute illness,[@b26] death in older patients hospitalised with heart failure,[@b27] and poor functional survival after cardiac surgery.[@b28] Few data on its predictive role in the setting of TAVI are available. A retrospective single-centre study (155 patients with severe AS, mean age 84 years) found that SPPB score was independently associated with the likelihood of unplanned readmission following TAVI, and that the addition of the SPPB to predictive clinical models increased discriminatory performance for predicting unplanned readmission and all-cause death.[@b29] A previous analysis of the CGA-TAVI registry found that the SPPB had value for predicting the likelihood of a composite of death and/or hospitalisation and a composite of death and/or non-fatal stroke within the first three months after TAVI.[@b5] In contrast, the current analysis did not find that SPPB score was an independent predictor of these outcomes at one year, although it did find it was predictive of a composite endpoint comprising all fatal and non-fatal complications. A high-risk SPPB score was associated with an increased likelihood of all-cause mortality and the composite of death and/or non-fatal stroke in univariate analysis, but significance was lost after adjustment for baseline characteristics in multivariate analysis, although the result for death and/or non-fatal stroke approached significance (*P* = 0.058).

The MPI is a multidimensional tool comprising eight different assessments. As part of the current study, we sought to identify whether there were clear associations between any individual components of the MPI and two composite outcomes at one year after TAVI. The only MPI components independently associated with the combined endpoint of death and/or stroke at one year were worse ADL score and worse ESS score, and the only components associated with the composite of death and/or re-hospitalization and/or stroke at one year were worse MNA score and worse ESS score. Few other studies have specifically reported on individual MPI components in TAVI patients. One study found that a low ADL score was independently predictive of long-term all-cause mortality after TAVI in elderly patients,[@b30] while two others found univariate associations between ADL score or MNA score and morbidity and mortality after TAVI.[@b15],[@b17]

The SPPB comprises balance testing, repeated chair stands, and time to walk eight feet.[@b7] In patients undergoing TAVI, slow gait speed has been shown to be associated with an increased risk of short- and mid-term mortality[@b31],[@b32] and with unplanned readmission[@b29]. Another study reported that a "timed get up and go" test had good predictive ability for mortality and major morbidity during the first year after TAVI.[@b15] The current study did not find any significant independent associations between individual components of the SPPB and composite endpoints comprising death and/or stroke or death and/or hospitalisation and/or stroke at one year, although the eight-foot walk was associated with both endpoints in univariate analysis.

The previous analysis of CGA-TAVI data found there was no significant changes in mean MPI score between baseline and three months, whereas mean SPPB score improved significantly.[@b5] In the current study, a worsening (increasing) MPI score at three months post-TAVI was associated with an increased risk of the composite endpoint of death and/or non-fatal stoke at one year in the adjusted analysis. No significant relationships between worsening SPPB and one-year outcome were found. Little information has been published about the relevance of changes in MPI score over time and no other studies evaluating changes in MPI score over time in TAVI patients were identified. One study involving elderly patients admitted to hospital with an acute illness or a relapse of chronic disease reported that changes in MPI score might be helpful for monitoring the evolution of a patient\'s clinical condition during a hospital stay.[@b33]

4.1. Limitations {#s4a}
----------------

This registry analysis provides useful data from a real-world perspective. Despite advanced age and high-risk status for aortic valve replacement, patients with low-risk results on either MPI or SPPB enjoyed excellent short-term and one-year outcomes. This can be particularly helpful with respect to very elderly patients, as this population is often excluded from clinical trials.

However, the observational nature of the study means there is a greater risk of missing data. In addition, the number of patients enrolled was modest, limiting the statistical power of the analysis and the generalisability of the data. Additional studies involving a larger number of participants would be helpful to confirm and expand on the results. The findings of this study are applicable to elderly patients at higher levels of surgical risk; additional evaluation of CGA and its components in other groups of elderly patients may be helpful, given the current shift towards performing TAVI in lower risk patients than in the past.

4.2. Conclusions {#s4b}
----------------

Baseline MPI score was an independent predictor of all-cause mortality and a composite of death and/or non-fatal stroke at one year after TAVI in elderly patients. A worsening MPI score at three months post-TAVI was also associated with an increased risk of death and/or non-fatal stoke at one year. SPPB score was not found to be an independent predictor of one-year post-TAVI outcomes. These findings need to be confirmed in a larger sample of TAVI patients.

A research grant was provided by Edwards Lifesciences (Nyon, Switzerland) to the Sponsor IPPMed (Cloppenburg, Germany). Peter Bramlage is the representative of IPPMed, Cloppenburg, Germany. Jan Baan received research funding from Edwards Lifesciences as did Andrea Ungar. Jean-Bernard Masson is a consultant for Edwards Lifesciences. Jana Kurucova and Martin Thoenes are employees of Edwards Lifesciences. The other authors declare no conflict of interest in relation to this manuscript. Data were captured using the s4trials Software provided by Software for Trials Europe GmbH, Berlin, Germany.
